Immune System Diseases Recruiting Phase 2 Trials for Sparsentan (DB12548)

Also known as: Immune System Disease

IndicationStatusPhase
DBCOND0029769 (Immune System Diseases)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04663204A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A NephropathyTreatment